The Access to Medicine Index (A): Engaging Stakeholders and Attracting Funding Custom Case Solution & Analysis

Section 1: Evidence Brief

Financial Metrics

• Initial Funding: The Dutch Ministry of Foreign Affairs provided 500,000 Euros in seed capital for the first ranking cycle.
• Budget Deficit: Estimated operational costs for a full biennial index cycle exceed 2 million Euros.
• Pharma Market Cap: The top 20 companies being indexed represent over 500 billion dollars in combined annual revenue.
• Funding Source Concentration: 100 percent of current funding is derived from public or philanthropic grants; zero revenue from commercial services or data licensing.

Operational Facts

• Index Cycle: Data collection and analysis require an 18 to 24 month period to produce a single ranking.
• Company Scope: The index targets the top 20 research-based pharmaceutical companies globally.
• Data Points: Evaluation covers seven technical areas including pricing, patents, and research and development for neglected diseases.
• Staffing: The foundation operates with a lean core team of fewer than 10 full-time employees, relying heavily on third-party consultants for data verification.

Stakeholder Positions

• Wim Leereveld (Founder): Seeks to create a competitive race to the top among pharma companies but faces immediate liquidity constraints.
• Bill and Melinda Gates Foundation: Potential anchor donor but requires proof of methodology rigor and industry buy-in before committing multi-year funds.
• Pharmaceutical Executives: Generally skeptical; fear the index will be used as a naming and shaming tool rather than a constructive benchmark.
• Institutional Investors: Express interest in using index data for Environmental, Social, and Governance (ESG) scoring but are not yet willing to pay for access.

Information Gaps

• Pharma Compliance Costs: The case does not quantify the internal man-hours required for a company to respond to the index questionnaire.
• Long-term Grant Stability: There is no evidence of a signed multi-year commitment beyond the initial Dutch grant.
• Data Accuracy: The case lacks a clear audit trail for self-reported data provided by companies that do not allow on-site verification.

Section 2: Strategic Analysis

Core Strategic Question

The Access to Medicine Index (ATMI) must resolve a fundamental tension: How can a non-profit entity establish enough institutional legitimacy to compel participation from a secretive industry while simultaneously securing a multi-million dollar funding base that does not compromise its independence?

Structural Analysis

• Bargaining Power of Suppliers (Data Providers): High. The index is worthless without data from the top 20 pharma companies. Since participation is voluntary, companies hold the power to starve the index of its primary input.
• Threat of Substitutes: Low. Existing ESG ratings are broad and lack the therapeutic depth of ATMI. However, internal CSR reports from companies serve as a low-credibility substitute.
• Value Chain Friction: The data collection process is currently a bottleneck. The transition from raw data to a ranked score requires specialized medical and financial expertise that the foundation cannot yet afford at scale.

Strategic Options

Option 1: The Investor-Led Model. Pivot the primary audience from NGOs to institutional investors. By aligning the index with financial materiality, ATMI can pressure pharma CEOs through their shareholders.

• Trade-offs: Increases index relevance to Wall Street but may dilute focus on the poorest patients in favor of market-based solutions.
• Resource Requirements: Hire 2-3 analysts with deep backgrounds in equity research and ESG integration.

Option 2: The Regulatory Integration Model. Focus on becoming the official benchmark for government procurement and WHO partnerships.

• Trade-offs: Ensures long-term funding from public sources but risks becoming a slow-moving bureaucratic tool.
• Resource Requirements: Significant lobbying and policy development presence in Geneva and Washington D.C.

Preliminary Recommendation

ATMI should pursue Option 1. The pharmaceutical industry is most responsive to capital market pressure. By positioning the index as a risk-management tool for investors, Leereveld can secure both industry participation and philanthropic funding from donors like the Gates Foundation who value market-based accountability.

Section 3: Implementation Roadmap

Critical Path

• Month 1-3: Methodology Hardening. Finalize the 2008 index indicators with explicit input from a technical advisory board to preempt industry criticism of unfair weighting.
• Month 4-6: Anchor Funding Launch. Secure a three-year commitment from the Gates Foundation by demonstrating signed letters of intent from at least 10 institutional investors who promise to use the index in their analysis.
• Month 7-18: Data Collection and Verification. Deploy a secure digital portal for company submissions to reduce manual processing errors and administrative friction.
• Month 19-24: Results Dissemination. Execute a high-profile launch at a major global forum (e.g., Davos) to maximize reputational stakes for the ranked companies.

Key Constraints

• Data Integrity: The reliance on self-reported data is the greatest operational vulnerability. One scandal involving falsified data from a ranked company could destroy index credibility permanently.
• Funding Volatility: The 2 million Euro requirement is lumpy. If the Gates Foundation grant is delayed, the foundation has no bridge financing to keep the technical team intact.

Risk-Adjusted Implementation Strategy

The foundation must operate on a modular budget. If the full 2 million Euros is not secured by Month 6, the index must scale back the number of therapeutic areas evaluated rather than compromising the depth of analysis for the remaining areas. Preserving the quality of the benchmark is more important than its breadth in the first two cycles.

Section 4: Executive Review and BLUF

BLUF

The Access to Medicine Index must transition from a founder-led project to an institutionalized market utility. To survive, the foundation must secure a 2.5 million Euro funding floor for the 2008 cycle while pivoting its value proposition to institutional investors. Survival depends on making the index a financial risk indicator rather than a moral report card. Without investor-led pressure, pharmaceutical companies will treat data requests as optional marketing exercises. Secure the Gates Foundation grant by demonstrating that the index changes the cost of capital for pharma, not just their public relations strategy. Approve the shift to an investor-centric model immediately to ensure the 2008 ranking has teeth.

Dangerous Assumption

The analysis assumes that pharmaceutical companies will continue to provide sensitive internal data for free. If a single industry leader like Pfizer or GSK refuses to participate, the index loses its competitive logic, and the remaining companies will likely follow suit to protect their own proprietary information.

Unaddressed Risks

• Methodology Creep: Adding too many indicators to satisfy diverse donors will make the index too complex for investors to use and too expensive for the foundation to audit. (Probability: High; Consequence: Moderate)
• Donor Interference: Heavy reliance on the Gates Foundation may lead to a perception of bias, especially if the index ranks companies that are major partners of the donor. (Probability: Moderate; Consequence: High)

Unconsidered Alternative

The team has not considered a fee-for-service model where the foundation provides confidential, deep-dive benchmarking reports to individual companies. While this raises conflict-of-interest concerns, it provides a path to financial self-sufficiency that does not rely on the whims of philanthropic grants.

MECE Assessment

• Mutually Exclusive: The strategic options distinguish clearly between investor-led, government-led, and status-quo paths.
• Collectively Exhaustive: The plan covers funding, methodology, and stakeholder management, which are the three pillars of index viability.

VERDICT: APPROVED FOR LEADERSHIP REVIEW